ArticleThe journal of sexual medicine2010
Adenosine deaminase enzyme therapy prevents and reverses the heightened cavernosal relaxation in priapism.
Article in The journal of sexual medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- An update on mechanisms and treatment options for priapism.Nature reviews. Urology · 2025Review
- Relationship between Dietary Patterns with Benign Prostatic Hyperplasia and Erectile Dysfunction: A Collaborative Review.Nutrients · 2021Review
- Article
- Targeted endothelial nanomedicine for common acute pathological conditions.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- Beneficial and detrimental role of adenosine signaling in diseases and therapy.Journal of applied physiology (Bethesda, Md. : 1985) · 2015Review
- Nitrergic Mechanisms for Management of Recurrent Priapism.Sexual medicine reviews · 2015Article
- How I treat priapism.Blood · 2015Article
- Article
- Molecular pathophysiology of priapism: emerging targets.Current drug targets · 2015Review
- Opiorphin is a master regulator of the hypoxic response in corporal smooth muscle cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2014Article
- The role of adenosine signaling in sickle cell therapeutics.Hematology/oncology clinics of North America · 2014Review
- Article
- Article
- Stuttering priapism: insights into pathogenesis and management.Current urology reports · 2012Review
- Adenosine signaling in normal and sickle erythrocytes and beyond.Microbes and infection · 2012Review
- Targeted interception of signaling reactive oxygen species in the vascular endothelium.Therapeutic delivery · 2012Review
- Priapism in sickle-cell disease: a hematologist's perspective.The journal of sexual medicine · 2012Review
- Article
- Impaired erectile function in CD73-deficient mice with reduced endogenous penile adenosine production.The journal of sexual medicine · 2011Article
- Priapism in hematological and coagulative disorders: an update.Nature reviews. Urology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
introductionPriapism featured with painful prolonged penile erection is dangerous and commonly seen in sickle cell disease (SCD). The preventive approaches or effective treatment options for the disorder are limited because of poor understanding of its pathogenesis. Recent studies have revealed a novel role of excess adenosine in priapism caused by heightened cavernosal relaxation, and therefore present an intriguing mechanism-based therapeutic possibility.
aimThe aim of this study was to determine the therapeutic effects of adenosine deaminase (ADA) enzyme therapy to lower adenosine in priapism.
methodsBoth ADA-deficient mice and SCD transgenic (Tg) mice display priapism caused by excessive adenosine. Thus, we used these two distinct lines of mouse models of priapism as our investigative tools. Specifically, we treated both of these mice with different dosages of polyethylene glycol-modified ADA (PEG-ADA) to reduce adenosine levels in vivo. At the end points of the experiments, we evaluated the therapeutic effects of PEG-ADA treatment by measuring adenosine levels and monitoring the cavernosal relaxation.
main outcome measuresAdenosine levels in penile tissues were measured by high-performance liquid chromatography, and cavernosal relaxation was quantified by electrical field stimulation (EFS)-induced corporal cavernosal strip (CCS) assays.
resultsWe found that lowering adenosine levels in penile tissues by PEG-ADA treatment from birth in ADA-deficient mice prevented the increased EFS-induced CCS relaxation associated with priapism. Intriguingly, in both ADA-deficient mice and SCD Tg mice with established priapism, we found that normalization of adenosine levels in penile tissues by PEG-ADA treatment relieved the heightened EFS-induced cavernosal relaxation in priapism.
conclusionsOur studies have identified that PEG-ADA is a novel, safe, and mechanism-based drug to prevent and correct excess adenosine-mediated increased cavernosal relaxation seen in two independent priapic animal models, and suggested its therapeutic possibility in men suffering from priapism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.